Format

Send to

Choose Destination
Curr Opin Investig Drugs. 2001 Sep;2(9):1247-9.

VasoCare. Vasogen.

Author information

1
University of Milan, Department of Pharmacological Sciences, Via Balzaretti 9, 20133, Milan, Italy. francesco.visioli@unimi.it

Abstract

Vasogen is developing VasoCare, an immune modulation therapy, as a potential treatment for peripheral vascular disease (PVD) and atherosclerosis [308287], [388266]. In December 1998, VasoCare was in late phase II trials in the UK for PVD [308287], and by October 2000, phase I/II trials were underway in the US, Canada and Europe [388254]. By March 2001, Vasogen was planning to launch a US multicenter trial in PVD in support of regulatory approval [402091]. In June 2001, the USPTO issued a patent entitled 'Method for Preventing and Reversing Atherosclerosis', covering the use of VasoCare in the prevention and reduction of atherosclerosis [411783].

PMID:
11717811
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center